Beacon Medical Interchange

beaconmedic.com

 

Beacon Medical Interchange
Avatar

Are Two Immunotherapy Agents Better than One? Was the MYSTIC Trial a Mistake?

By Beacon Medical Interchange FEATURING Jack West
By Beacon Medical Interchange FEATURING Jack West
9 views
November 2, 2018
Dr. Jack West reviews the promise of combinations of immunotherapies for advanced NSCLC and the ...
read more ↘
0 Comments
Login to view comments. Click here to Login

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Lung
14:11
Beacon Medical Interchange

Key Findings From Study on Plasma-Based TMB as a Predictive Biomarke…

Feat. J. West, C. Aggarwal
08:34
Beacon Medical Interchange

Status of TMB as a Biomarker in NSCLC & Clinical Utility of Nega…

Feat. J. West, C. Aggarwal
09:09
Beacon Medical Interchange

Best Treatment First: Implications for Front - Loading Combinations …

Feat. J. West
09:07
Beacon Medical Interchange

How do Patients with Advanced NSCLC on Daily Steroids Do on Immune C…

Feat. J. West
07:05
Beacon Medical Interchange

FDA Approval of Dacomitinib for NSCLC - Is it the Gamechanger in the…

Feat. J. West
10:16
Beacon Medical Interchange

Is Progression-Free Survival without Overall Survival Benefit Enough?

Feat. J. West
07:12
Beacon Medical Interchange

Small Trial Shows Big Risks of First Line Pembro to EGFR Mutation-Po…

Feat. J. West
08:57
Beacon Medical Interchange

Nivo/Ipi Rx of Choice for Adv. NSCLC, PD-L1 Under 1%, High TMB? New …

Feat. J. West
09:33
Beacon Medical Interchange

Practice Changing Positive Keytruda Trial : Chemo +IO had significan…

Feat. J. West
11:06
Beacon Medical Interchange

KEYNOTE-042: Should Pembrolizumab Replace Chemo for Broader Populati…

Feat. J. West
10:18
Beacon Medical Interchange

My Top 5 ASCO 2018 Abstracts in Advanced NSCLC

Feat. J. West
07:13
Beacon Medical Interchange

My Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung C…

Feat. J. West
15:37
Beacon Medical Interchange

Local Therapy for Advanced NSCLC: Revising Outdated Principles for S…

Feat. J. West
12:38
Beacon Medical Interchange

Is Chemo the Key for EGFR Mutation-Positive NSCLC? The Data Too Good…

Feat. J. West
08:10
Beacon Medical Interchange

IMpower131: Role for Carbo/Nab-Paclitaxel/Atezolizumab Combo for Adv…

Feat. J. West
13:08
Beacon Medical Interchange

Nivo/Ipi vs. Chemo in High TMB Advanced NSCLC: Key Results from Chec…

Feat. J. West
09:40
Beacon Medical Interchange

Are TMB and Nivolumab/Ipilimumab Ready for Clinical Use? Insights fr…

Feat. J. West
06:32
Beacon Medical Interchange

KEYNOTE-189: Clinical Implications in Patients with Less Than 1% Tum…

Feat. J. West
06:16
Beacon Medical Interchange

KEYNOTE-189: Clinical Implications in Patients with Low (1-49%) Tumo…

Feat. J. West
07:59
Beacon Medical Interchange

KEYNOTE-189: Clinical Implications for High Tumor PD-L1 Expression

Feat. J. West
05:03
Beacon Medical Interchange

Is Chemotherapy More Effective After Prior Immunotherapy?

Feat. J. West
11:35
Beacon Medical Interchange

New Insights on Acq. Resistance to Immune Checkpoint Inhibitors for …

Feat. J. West
13:06
Beacon Medical Interchange

Pembro + Chemo in Metastatic NSCLC - Key Summary of a Practice-Chang…

Feat. J. West
09:15
Beacon Medical Interchange

Chemo/Immunotherapy in Advanced Squamous NSCLC: What is the Impact o…

Feat. J. West
06:36
Beacon Medical Interchange

Afatinib in Patients With Uncommon EGFR Mutations In NSCLC

Feat. J. West
07:21
Beacon Medical Interchange

How Should We Monitor Patients After Potentially Curative Lung Cance…

Feat. J. West
07:01
Beacon Medical Interchange

Diminishing Returns after a Fixed Duration of Immunotherapy Treatmen…

Feat. J. West
02:40
Beacon Medical Interchange

Is There Still a Value in Testing for PD-L1 Expression in Advanced N…

Feat. J. West
03:35
Beacon Medical Interchange

Better Communication Leads to Better Outcomes for Cancer Patients

Feat. J. West
06:24
Beacon Medical Interchange

Are Two Immunotherapy Agents Better than One? Was the MYSTIC Trial a…

Feat. J. West
10:26
Beacon Medical Interchange

Is Immunotherapy Ineffective for Driver Mutation-positive Advanced N…

Feat. J. West
06:33
Beacon Medical Interchange

Is Durvalumab Curing Patients or Just Treating Metastatic Disease Ea…

Feat. J. West
07:44
Beacon Medical Interchange

Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Standard of C…

Feat. J. West
08:13
Beacon Medical Interchange

Has the KEYNOTE-189 Trial Defined a Clear Standard of Care in Metast…

Feat. J. West
10:20
Beacon Medical Interchange

Is There a Better Lung Immunotherapy Biomarker than PD-L1?

Feat. J. West
11:29
Beacon Medical Interchange

Atezolizumab in First Line Metastatic NSCLC: Early Clinical Results …

Feat. J. West
08:55
Beacon Medical Interchange

Genomic Sequencing for All Solid Tumors: Where Will This Lead Us?

Feat. J. West
06:25
Beacon Medical Interchange

Dabrafenib/Trametinib for BRAF V600E Mutation-Positive Advanced NSCLC

Feat. J. West
11:47
Beacon Medical Interchange

Osimertinib as First-Line Treatment for EGFR Mutation-Positive Advan…

Feat. J. West
07:54
Beacon Medical Interchange

Dacomitinib: Dark Horse EGFR TKI Charges into First Line Setting for…

Feat. J. West
05:53
Beacon Medical Interchange

Are PD-1/PD-L1 Immune Checkpoint Inhibitors Completely Interchangeab…

Feat. J. West
07:02
Beacon Medical Interchange

Will Immunotherapy Shift Treatment Balance for Borderline Resectable…

Feat. J. West
10:03
Beacon Medical Interchange

Research Question or Standard of Care: The Barriers to Broad Adoptio…

Feat. J. West
07:22
Beacon Medical Interchange

Hyper-Progressive Disease on Immunotherapy in Advanced NSCLC

Feat. J. West
09:09
Beacon Medical Interchange

Tumor Mutational Burden in SCLC: A Valuable Immunotherapy Biomarker?

Feat. J. West
06:56
Beacon Medical Interchange

Chemo/Immunotherapy Data Increasingly Compelling with Additional Fol…

Feat. J. West
09:36
Beacon Medical Interchange

The FLAURA Trial: Practice-Changing Results for EGFR Mutation-Positi…

Feat. J. West
06:20
Beacon Medical Interchange

Immunotherapy in Stage III NSCLC: Practice-Changing Results of PACIF…

Feat. J. West
04:51
Beacon Medical Interchange

Early Returns on FLAURA Trial: Osimertinib as First Line Agent in EG…

Feat. J. West
04:19
Beacon Medical Interchange

Immunotherapy in Locally Advanced NSCLC - PACIFIC Study Shows Durval…

Feat. J. West
07:19
Beacon Medical Interchange

IMpower133: Is there Finally a New Standard of Care for Extensive St…

Feat. J. West
07:22
Beacon Medical Interchange

Updated Results on PACIFIC Trial: Revise Who Should Receive Consolid…

Feat. J. West
08:04
Beacon Medical Interchange

Long-Term Management on Immunotherapy for Advanced NSCLC: Insights f…

Feat. J. West
04:14
Beacon Medical Interchange

Pembrolizumab for PS2 Patients with Adv. NSCLC: Results of the PePS2…

Feat. J. West
06:39
Beacon Medical Interchange

The IMpower132 Trial: Does This Change the Advanced NSCLC Landscape?

Feat. J. West
09:43
Beacon Medical Interchange

The MYSTIC Trial has Failed on OS in Advanced NSCLC: What Does and D…

Feat. J. West
09:54
Beacon Medical Interchange

OS for Local Ablative Therapy for Oligometastatic NSCLC: Does it Fit…

Feat. J. West
09:59
Beacon Medical Interchange

Chemotherapy With or Without Immunotherapy in Stage IV Non-squamous …

Feat. J. West
08:59
Beacon Medical Interchange

Nivolumab vs. Chemo in Relapsed SCLC (review of Checkmate-331 trial)

Feat. J. West
13:29
Beacon Medical Interchange

Top 5 Most Influential Trial Findings in Lung Cancer Management in 2…

Feat. J. West
20:37
Beacon Medical Interchange

What is the Optimal Duration for Immunotherapy in Responding Patient…

Feat. J. West, D. Spigel
19:08
Beacon Medical Interchange

Changes in Lung Cancer Management, Addressing Stigma, and the Rise o…

Feat. J. Schiller, J. West
25:18
Beacon Medical Interchange

Overcoming Barriers in Cancer Care Delivery, Smoking Cessation, and …

Feat. G. Morgan, J. West
19:06
Beacon Medical Interchange

Weighing Clinical Significance of New Clinical Trial Results With Im…

Feat. J. West, C. Langer
25:42
Beacon Medical Interchange

Chest CT Screening and Pulmonary Workups in Lung Cancer Beyond Terti…

Feat. J. West, J. Gorden
20:09
Beacon Medical Interchange

Defining the Role of Interventional Pulmonology in Lung Cancer Manag…

Feat. J. West, J. Gorden
20:09
Beacon Medical Interchange

Why is Broader FDA Approval of First Pembrolizumab Monotherapy (KEYN…

Feat. J. West
26:53
Beacon Medical Interchange

Growing Momentum for Plasma-based Next Generation Sequencing in Adva…

Feat. J. West, C. Aggarwal
19:58
Beacon Medical Interchange

Current Practice & Challenges in Execution of Genomic Testing in…

Feat. J. West, G. Riely
28:12
Beacon Medical Interchange

Should Local Ablation Therapy in Oligometastatic or Oligoprogressing…

Feat. J. West, G. Riely
18:01
Beacon Medical Interchange

Critical Review of Combining Radiation with Immunotherapy in Advance…

Feat. J. West
31:09
Beacon Medical Interchange

Open Questions in Radiation Oncology Care: From Proton Beam Radiatio…

Feat. J. West, D. Palma
12:47
Beacon Medical Interchange

Immunotherapy-Based Options for NSCLC: How to Decide Which Approach …

Feat. J. West, C. Aggarwal